CIBC Private Wealth Group LLC Sells 5,141 Shares of Charles River Laboratories International, Inc. $CRL

CIBC Private Wealth Group LLC reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 34.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,728 shares of the medical research company’s stock after selling 5,141 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Charles River Laboratories International were worth $1,522,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CRL. Jones Financial Companies Lllp increased its position in shares of Charles River Laboratories International by 167.6% during the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after purchasing an additional 1,074 shares in the last quarter. Empowered Funds LLC acquired a new position in Charles River Laboratories International in the first quarter valued at about $418,000. Allworth Financial LP boosted its position in Charles River Laboratories International by 172.7% in the second quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after buying an additional 190 shares in the last quarter. Creative Planning grew its stake in Charles River Laboratories International by 7.1% during the second quarter. Creative Planning now owns 8,894 shares of the medical research company’s stock worth $1,349,000 after buying an additional 586 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in shares of Charles River Laboratories International by 57.4% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 17,977 shares of the medical research company’s stock worth $2,728,000 after buying an additional 6,558 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Price Performance

CRL opened at $153.52 on Monday. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $228.88. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02. The company’s 50 day simple moving average is $185.42 and its 200-day simple moving average is $180.83. The stock has a market capitalization of $7.56 billion, a P/E ratio of -51.86, a price-to-earnings-growth ratio of 2.63 and a beta of 1.64.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The firm had revenue of $994.23 million during the quarter, compared to analysts’ expectations of $986.98 million. During the same quarter in the previous year, the company posted $2.66 EPS. Charles River Laboratories International’s revenue was down .8% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on CRL shares. Wall Street Zen cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Morgan Stanley set a $185.00 price target on Charles River Laboratories International in a report on Monday, December 1st. Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, January 21st. JPMorgan Chase & Co. boosted their price objective on Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. Finally, Bank of America upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price on the stock in a report on Monday, December 15th. Ten investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $206.15.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.